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Background: A vast amount of literature describes the incidence of fracture as a risk for recurrent osteoporotic
fractures in western and Asian countries. Osteoporosis evaluation and treatment after a low-trauma fracture,
however, has not been well characterized in postmenopausal women in Asia. The purpose of this study was to
characterize patient and health system characteristics associated with the diagnosis and management of
osteoporosis among postmenopausal women hospitalized with a fragility fracture in Asia.
Methods: Patient surveys and medical charts of postmenopausal women (N=1,122) discharged after a fragility hip
fracture from treatment centers in mainland China, Hong Kong, Singapore, South Korea, Malaysia, Taiwan, and
Thailand between July 1, 2006 and June 30, 2007 were reviewed for bone mineral density (BMD) measurement,
osteoporosis diagnosis, and osteoporosis treatment.
Results: The mean (SD) age was 72.9 (11.5) years. A BMD measurement was reported by 28.2% of patients, 51.5%
were informed that they had osteoporosis, and 33.0% received prescription medications for osteoporosis in the
6 months after discharge. Using multivariate logistic regression analyses, prior history of fracture decreased the odds
of a BMD measurement (OR 0.63, 95% CI 0.45-0.88). Having a BMD measurement increased the odds of
osteoporosis diagnosis (OR 10.1, 95% CI 6.36-16.0), as did having health insurance (OR 4.95, 95% CI 1.51-16.21 for
private insurance with partial self-payment relative to 100% self-payment). A history of fracture was not
independently associated with an osteoporosis diagnosis (OR 0.80, 95% CI 0.56-1.15). Younger age reduced the
odds of receiving medication for osteoporosis (OR 0.59, 95% CI 0.36-0.96 relative to age ≥65), while having a BMD
measurement increased the odds (OR 1.79, 95% CI 1.23-2.61).
Conclusions: Osteoporosis diagnosis and treatment in Asian countries were driven by BMD measurement but not
by fracture history. Future efforts should emphasize education of general practitioners and patients about the
importance of fracture.
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Table 1 Patient characteristics
n Na (%)b
Age category (years)
<50 41 1,122 (3.7)
50-64 188 1,122 (16.8)
≥65 893 1,122 (79.5)
BMD measurement 316 837 (28.2)
Been told had osteoporosis 579 1,122 (51.5)
Prescription drug for osteoporosis 370 1,122 (33.0)
Histories
History of fragility fracture 174 1,081 (16.1)
Falls in past 12 months 278 1,051 (24.8)
Family history of osteoporosis 70 777 (6.2)
Family history of fracture 113 872 (10.1)
Corticosteroid use 41 972 (3.7)
Comorbidities
Arthritis 103 889 (9.2)
Hypertension 593 1,048 (52.9)
Diabetes 329 975 (29.3)
Stroke 125 920 (11.1)
Depression 36 894 (3.2)
Parkinson’s disease 32 892 (2.9)
Type of payment
100% self pay 260 1,069 (23.2)
Partial self pay with social insurance 458 1,069 (40.8)
Partial self pay with private insurance 25 1,069 (2.2)
100% paid by social insurance 100 1,069 (8.9)
100% paid by private insurance 23 1,069 (2.0)
Hospital treatment free of charge 41 1,069 (3.7)
Others 162 1,069 (14.4)
aNumber of “yes” or “no” responses. Patients who did not respond to
questions were treated as missing values and not included.
bAs a percent of 1,122.
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The prevalence of osteoporosis increases markedly after
age 50 in postmenopausal women in Asia [1-3]. In Korea
the prevalence of osteoporosis measured by bone mineral
density (BMD) scanning of the lumbar spine has been
reported to be 31% in postmenopausal women 45–64 years,
53% in those 65–74 years, and 69% in those ≥75 years [3].
Similar observations have been made in Taiwan [1].
A definitive diagnosis of osteoporosis in asymptomatic
women is achieved via BMD measurement but, because of
the relatively high cost of these measurements, a case-
finding strategy is recommended [4]. A simple risk index
based only on age and body weight can be used to screen
for osteoporosis in Asian postmenopausal women prior to
BMD measurement [5-8]. Since prior fracture is a well-
documented risk factor for a future non-vertebral osteo-
porotic fracture in postmenopausal women in western
and Asian countries [9-11], therefore, it is recommended
that after a fragility fracture all postmenopausal women
should be evaluated for osteoporosis [12]. Recent studies
in western countries indicate that rates of treatment with
medications for osteoporosis after a fracture vary widely.
In a study in Italy 78% of patients received a medication
for osteoporosis after a hip fracture [13]. Conversely, in
the Netherlands only 19% of women age ≥50 years were
treated with medications for osteoporosis in the year after
a low-trauma fracture [14] and in Belgium only 6% of
postmenopausal women received a bisphosphonate or
hormone therapy after a hip fracture [15].
Little is known, however, about osteoporosis evalu-
ation and treatment after a low-trauma fracture in coun-
tries in Asia. The objective of this study was to evaluate
the diagnosis and treatment of osteoporosis among post-
menopausal women after hospitalization for a fragility
fracture in a selection of Asian countries.
Methods
Study design and patient sample
This was a patient survey and medical chart review carried
out at multiple centers in six Asian countries including
mainland China, Hong Kong, Singapore, South Korea,
Malaysia, Taiwan, and Thailand. Women who were hospi-
talized due to fragility fracture of the hip between July 1st,
2006 and June 30th, 2007 (the case identification period)
were identified using discharge records of participating
hospitals. A random sample of these patients was selected
for inclusion in the study. Patients were included if they
had been hospitalized because of non-traumatic hip frac-
ture (defined as resulting from a fall from standing
height), were postmenopausal, and were able to participate
independently in an interview. The index fracture, i.e., the
fracture qualifying the subject for enrollment, was identi-
fied by reviewing hospitalization, emergency room or out-
patient visit records for ICD-9/10 diagnosis codes 820.0,820.2, or 820.8. Approval was obtained from participating




Medical charts were reviewed during hospitalization to
obtain data on BMD (T-score for spine, femoral neck, or
total hip), height and weight, comorbidities, and medica-
tions prescribed for osteoporosis.
Patient questionnaire
Face-to-face and telephone interviews were conducted
with patients to collect data about an osteoporosis diag-
nosis, BMD measurement, and osteoporosis treatment
in the 6-month period following hospitalization for
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been told that you have osteoporosis?” If they answered
“yes”, they were asked when they were told they had
osteoporosis (in relation to the index fracture). They
were also asked whether and when they had a BMD
measurement for osteoporosis and what reimbursement,
if any, they received for their hospital stay. Response
options were either items in a checklist or “yes”, “no”, or
“don’t know”. Questions about their post-fracture
follow-up included whether they were advised to take
prescription drugs or dietary supplements in the
6 month period after hospitalization for the index frac-
ture, whether they were still being treated by a phy-
sician for osteoporosis, and the specialty of the
physician. Other items recorded their demographic
and, clinical characteristics and their fracture history
prior to the index fracture.
Statistical analysis
The main outcome variables were binary variables (yes/no)
for a BMD measurement, an osteoporosis diagnosis, and
receipt of an osteoporosis medication. The associations be-
tween patient characteristics (age category, fracture history,
and payment type) and the outcome variables were exam-
ined in univariate analyses; P values were computed using
Fisher’s exact test. Logistic regression analyses were applied













100% self pay 19.7
Partial self pay with social insurance 25.9
Partial self pay with private insurance 1.4
100% paid by social insurance 7.3
100% paid by private insurance 1.3
Hospital treatment free of charge 3.4
Others 11.2
Unknown insurance 29.7
aP-value for Fisher’s exact test.the outcome variables BMD measurement, osteoporosis
diagnosis and receipt of medications. For the model with
BMD screening as outcome variable, independent variables
were age category, history of fracture, and payment type.
Only patients who answered “yes” or “no” were included in
the model with a BMD measurement as dependent va-
riable; patients who responded “don’t know” were
excluded. For the model with osteoporosis diagnosis as
outcome variable, independent variables included were
age category, fracture history, BMD measurement and
type of payment. For the model with receipt of osteo-
porosis medications as outcome variable, independent
variables included were age category, fracture history,
fracture diagnosis timing, BMD measurement and type
of payment.
A subgroup analysis assessed the impact of lower
BMD on osteoporosis diagnosis and receipt of osteopor-
osis medications among patients whose BMD values
were recorded. BMD values were expressed as a categor-
ical variable, and Fisher’s exact test was applied. BMD of
the total spine, femoral neck, or total hip was used in
the stated order as available. A logistic regression model
was applied to this patient subset, with osteoporosis
treatment as dependent variable and the following inde-
pendent variables: age category, a history of fracture,
and T score category. Percent of patients using osteopor-























Table 3 Logistic regression analyses
BMD measurement (N=837) Osteoporosis diagnosis Osteoporosis medication
OR (95% CI) OR (95% CI) OR (95% CI)
Age
20- 49 1.38 (0.35 -5.51) 0.6 (0.18-2.00) N/A
50-64 1.36 (0.91-2.05) 1.19 (0.77-1.84) 0.59 (0.36-0.96)
65+ Reference Reference Reference
Fracture history
Yes 0.63 (0.45-0.88) 0.80 (0.56-1.15) 1.05 (0.71-1.54)
No Reference Reference Reference
Fracture diagnosis timing
Before index fracture N/A N/A 0.99 (0.64-1.52)
During index fracture N/A N/A 1.38 (0.87-2.18)
After index fracture N/A N/A Reference
Unknown N/A N/A 0.28 (0.05-1.47)
A BMD measurement
Yes N/A 10.1 (6.36-16.0) 1.79 (1.23-2.61)
Unknown N/A 0.06 (0.03-0.10 1.48 (0.59-3.74)
No N/A Reference Reference
Type of payment
100% private insurance 8.19 (2.63 -25.58) 0.72 (0.20-2.54) 2.03 (0.54-7.66)
100% social insurance 1.96 (1.09 -3.50) 0.47 (0.27-0.84) 0.18 (0.07-0.51)
Other type of insurance 5.08 (3.11 -8.30) 2.48 (1.45-4.25) 2.45 (1.40-4.29)
Unknown insurance 1.33 (0.62-2.83) 0.39 (0.19-0.80) 1.05 (0.38-2.92)
Free hospital, government pay 4.13 (2.00-8.54) 1.31 (0.57-3.03) 1.56 (0.66-3.70)
Partial self with private insurance 3.43 (1.19-9.86) 4.95 (1.51-16.21) 0.49 (0.15-1.59)
Partial self with social insurance 3.94 (2.61 -5.95) 1.89 (1.28-2.81) 0.72 (0.45-1.15)
100% self pay Reference Reference Reference
N/A, not applicable.
Table 4 Osteoporosis diagnosis and treatment among the




A total of 1,148 post-menopausal women hospitalized
due to fragility fractures met the inclusion criteria and
were enrolled in the study. Of these, 26 (2.3%) patients
did not answer the question about an osteoporosis diag-
nosis and were excluded from the analysis. The data
analysis was applied to the remaining 1,122 subjects.subgroup of patients with a BMD measurement




Greater than −1 23 (9.0) 60.9 43.8
−1 to −2.5 103 (40.2) 70.0 59.2
−2.5 to −3 39 (15.2) 92.3 61.5
Lower than −3 91 (35.6) 82.4 78.0
Total 256 (100) 77.0 64.8
aP=0.003 (Fisher’s exact test).Patient characteristics
Patient characteristics are presented in Table 1. The
mean (SD) age was 72.9 (11.5) years. A history of fragil-
ity fracture prior to the hip fracture was recorded in
16.1% of patients, 52.9% had hypertension and 29.3%
had diabetes. The most frequent types of payment were
“partial self pay with social insurance” (40.8%) and
“100% self pay” (23.2%).BMD measurement
A BMD measurement prior to hip fracture was reported
by 28.2% of the 837 patients who answered “yes” or “no”
to the BMD measurement question (Table 1). Age cat-
egory, a history of fracture, and type of payment were
associated with having had a BMD measurement in the
Table 5 Osteoporosis treatments
(%) (N=1,122)
Prescription medications for osteoporosisa














aMedications used by >2.0% of patients are listed.
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model (Table 3), the variables independently associated
with having had a BMD measurement were fracture his-
tory (a history of fracture reduced the odds of a BMD
measurement) and type of insurance (compared to 100%
self pay, all specified types of insurance increased the odds


































BMD measurement, %* Osteoporosis dia
P<0.001 (Fisher’s exact test)
Figure 1 BMD measurement, osteoporosis diagnosis and treatment, bOsteoporosis diagnosis
Over half of the patients (51.5%) reported that they had
been told they had osteoporosis (Table 1). Older age cat-
egory, a history of fracture, and type of payment were
significantly associated with an osteoporosis diagnosis
(Table 2). In logistic regression analysis having had a
BMD measurement and type of payment were associated
with an osteoporosis diagnosis: compared to individuals
with 100% self pay, the odds of an osteoporosis diagnosis
were decreased among patients with 100% social insur-
ance and increased among patients with partial self pay-
ment with private or social insurance, and among those
with “other type of insurance” (Table 3). However, a frac-
ture history was not significantly associated with an
osteoporosis diagnosis. T scores were available for 256
patients. A lower T score was more likely associated with
an osteoporosis diagnosis in the univariate analysis
(Table 4).Osteoporosis treatment
Only 33.0% of patients received prescription medications
for osteoporosis in the 6 months after the index fracture
(Table 1). A bisphosphonate was prescribed for 26% of
patients, representing 79% of prescription medications
for osteoporosis (Table 5). Calcitonin was the most fre-
quent non-bisphosphonate therapy, used by 4.8% of
patients. Half of the patients (50.3%) used dietary sup-








gnosis, % Osteoporosis medication, %*
y country. P<0.001 (Fisher’s exact test).
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cantly associated with treatment for osteoporosis in uni-
variate analyses (Table 2). Age category, having had a
BMD measurement, fracture history and type of pay-
ment were associated with osteoporosis treatment in
multivariate logistic analysis (Table 3). Younger age
category (50–64 years) reduced the odds of receiving
medication for osteoporosis, while having had a BMD
measurement increased the odds of treatment. The odds
of treatment were reduced by having 100% social insur-
ance and increased by “other type of insurance” when
compared to 100% self pay. A history of fracture was not
associated with receiving medications for osteoporosis.
A more negative T score was associated with osteopor-
osis treatment in the univariate analysis (Table 4).
Rates of BMD measurement, osteoporosis diagnosis and
treatment, by country
Korea and Thailand were the top ranking countries for
rates of BMD measurement, osteoporosis diagnosis, and
osteoporosis treatment (Figure 1). Malaysia was the only
country in which the rate of osteoporosis treatment
exceeded the rate of diagnosis. Rates of diagnosis and
treatment exceeded rates of BMD testing in all countries
except mainland China and Singapore.
In this population of elderly (average age 72.9 years)
women discharged from hospital after a fragility fracture,
having a BMD measurement (28.2% of patients) increased
the odds of a diagnosis of osteoporosis and treatment.
Compared to 100% self-payment, having any known type
of health insurance increased the odds of a BMD
measurement-suggesting an unwillingness to pay out of
pocket for preventive care-while having 100% social insur-
ance reduced both the odds of receiving prescription med-
icines for osteoporosis and the odds of an osteoporosis
diagnosis-almost half (48.5%) of the patients had not been
told that they had osteoporosis.
Among the 41% of patients who reported their physi-
cian’s specialty, the same percentage (29%) of orthopedic
specialists and general practitioners (GPs) prescribed medi-
cations for osteoporosis. However, information about
osteoporosis was communicated to patients largely by
orthopedic specialists (76%) rather than by GPs (11%), sug-
gesting that GPs need more education about osteoporosis.
Results of this study suggest that greater attention should
be paid to patients with a history of fracture. A history of
fracture, recorded for 13.2% of patients, was not signifi-
cantly associated with an osteoporosis diagnosis independ-
ently of other factors-BMD, age, payment type-or with
receiving medications for osteoporosis medications after
the index fracture. The only statistically significant sequelae
of a history of prior fracture was that it reduced the odds
of a BMD measurement-perhaps because physicians
deduced that a prior fracture was indicative ofosteoporosis, obviating the need for a BMD test. A recur-
rent fracture after the index fracture was experienced by
9% of the patients in this study. A history of prior fracture
was a significant independent predictor of a recurrent fac-
ture (OR 1.67, 95% CI 1.02-2.72), while other factors (age,
an osteoporosis diagnosis, a BMD measurement) were not
significantly predictive.
Summary
In this study, an average of 33.0% of patients received a
prescription medication for osteoporosis in the 6 months
after the index fracture, though this varied from 6.5% in
mainland China to 63.5% in Thailand. These rates are
comparable or better than recent practice recorded in
Western countries. In a 2003–04 UK study of patients
(97% women) after a fracture of the distal radius, 8.5%
were referred for BMD scanning, calcium and vitamin D
was prescribed to 22%, and bisphosphonates to 9% [16].
In a 2006 study set in Sweden, management of patients
post fracture depended on the results of a BMD scan
[17]. In the three years after the fracture, antiresorptive
medicines (excluding calcium-vitamin D) had been
received by two thirds of osteoporotic, one sixth of
osteopenic, and none of the patients with normal BMD
[17]. There is little recent data for the United States, and
most studies of medical practice after low-trauma or hip
fracture relate to small single-center studies in the
1990s. Among these US studies the median rate of pre-
scribed medicines for osteoporosis after a fracture was
24% (range 5-60%) [18-24].
Conclusions
Even after experiencing a fragility fracture, 48.5% of
Asian postmenopausal women reported that they had
not been told that they had osteoporosis and only 33.0%
were receiving prescription medications for osteoporosis.
A history of fracture did not increase the odds of an
osteoporosis diagnosis or treatment, indicating that both
patients and GPs should be educated about the import-
ance of fractures in the evaluation of osteoporosis.
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